BACKGROUND: Hepatotoxicity, gastrointestinal complaints and general malaise are common limiting adverse reactions of azathioprine and mercaptopurine in IBD patients, often related to high steady-state 6-methylmercaptopurine ribonucleotide (6-MMPR) metabolite concentrations. AIM: To determine the predictive value of 6-MMPR concentrations 1 week after treatment initiation (T1) for the development of these adverse reactions, especially hepatotoxicity, during the first 20 weeks of treatment. METHODS: The cohort study consisted of the first 270 IBD patients starting thiopurine treatment as part of the Dutch randomised-controlled trial evaluating pre-treatment thiopurine S-methyltransferase genotype testing (ClinicalTrials.gov NCT00521950). Blood...
BACKGROUND AND AIMS: Only a quarter of thiopurine-induced myelotoxicity in IBD patients is related t...
BACKGROUND AND AIMS: Only a quarter of thiopurine-induced myelotoxicity in inflammatory bowel diseas...
Contains fulltext : 169964.pdf (publisher's version ) (Closed access)BACKGROUND AN...
BACKGROUND: Hepatotoxicity, gastrointestinal complaints and general malaise are common limiting adve...
BACKGROUND: Hepatotoxicity, gastrointestinal complaints and general malaise are common limiting adve...
BACKGROUND: Hepatotoxicity, gastrointestinal complaints and general malaise are common limiting adve...
BackgroundHepatotoxicity, gastrointestinal complaints and general malaise are common limiting advers...
BackgroundHepatotoxicity, gastrointestinal complaints and general malaise are common limiting advers...
BackgroundHepatotoxicity, gastrointestinal complaints and general malaise are common limiting advers...
BackgroundHepatotoxicity, gastrointestinal complaints and general malaise are common limiting advers...
Contains fulltext : 169966.pdf (publisher's version ) (Closed access)BACKGROUND: H...
BACKGROUND: Approximately 25% of patients with inflammatory bowel disease (IBD) discontinue azathiop...
BACKGROUND: Approximately 25% of patients with inflammatory bowel disease (IBD) discontinue azathiop...
BACKGROUND: Approximately 25% of patients with inflammatory bowel disease (IBD) discontinue azathiop...
BACKGROUND AND AIMS: Only a quarter of thiopurine-induced myelotoxicity in IBD patients is related t...
BACKGROUND AND AIMS: Only a quarter of thiopurine-induced myelotoxicity in IBD patients is related t...
BACKGROUND AND AIMS: Only a quarter of thiopurine-induced myelotoxicity in inflammatory bowel diseas...
Contains fulltext : 169964.pdf (publisher's version ) (Closed access)BACKGROUND AN...
BACKGROUND: Hepatotoxicity, gastrointestinal complaints and general malaise are common limiting adve...
BACKGROUND: Hepatotoxicity, gastrointestinal complaints and general malaise are common limiting adve...
BACKGROUND: Hepatotoxicity, gastrointestinal complaints and general malaise are common limiting adve...
BackgroundHepatotoxicity, gastrointestinal complaints and general malaise are common limiting advers...
BackgroundHepatotoxicity, gastrointestinal complaints and general malaise are common limiting advers...
BackgroundHepatotoxicity, gastrointestinal complaints and general malaise are common limiting advers...
BackgroundHepatotoxicity, gastrointestinal complaints and general malaise are common limiting advers...
Contains fulltext : 169966.pdf (publisher's version ) (Closed access)BACKGROUND: H...
BACKGROUND: Approximately 25% of patients with inflammatory bowel disease (IBD) discontinue azathiop...
BACKGROUND: Approximately 25% of patients with inflammatory bowel disease (IBD) discontinue azathiop...
BACKGROUND: Approximately 25% of patients with inflammatory bowel disease (IBD) discontinue azathiop...
BACKGROUND AND AIMS: Only a quarter of thiopurine-induced myelotoxicity in IBD patients is related t...
BACKGROUND AND AIMS: Only a quarter of thiopurine-induced myelotoxicity in IBD patients is related t...
BACKGROUND AND AIMS: Only a quarter of thiopurine-induced myelotoxicity in inflammatory bowel diseas...
Contains fulltext : 169964.pdf (publisher's version ) (Closed access)BACKGROUND AN...